Navigation Links
AbbVie to Host Fourth-Quarter and Full-Year 2013 Earnings Conference Call
Date:1/13/2014

NORTH CHICAGO, Ill., Jan. 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2013 financial results on Friday, Jan. 31, 2014, before the market opens.

AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern). It will be accessible through AbbVie's Investor Relations website at www.abbvieinvestor.com. An archived edition of the call will be available after 11 a.m. Central time.

About AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employed approximately 21,000 people worldwide and marketed medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.


'/>"/>
SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C
2. AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Percent SVR12 in Genotype 1 Hepatitis C Patients New to Therapy
3. U.S. Gastroenterologists Have Increased Their TNF-alpha Inhibitor Use Since 2012, Especially for AbbVies Humira, as a Result of Its Recent Approval in Ulcerative Colitis
4. Financial Results, New Drug Applications, and Stock Price Movements - Research Report on Endo, Bristol-Myers Squibb, Express Scripts, AbbVie, and Incyte
5. AbbVie Reports Third-Quarter 2013 Financial Results
6. AbbVie Named a Science Top Employer
7. AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
8. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
9. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
10. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
11. AbbVie Declares Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 UBM Medica US announces that  ... to help oncologists and other clinicians gain a better ... of targeted therapies and immunotherapies, discusses some of the ... Every September, Blood Cancer Awareness Month ... about blood cancers—helping to increase survival rates and improve ...
(Date:9/19/2014)... 19, 2014  Pressure BioSciences, Inc. (OTCQB: PBIO) ... received and approved all parts required to build ... begun to manufacture the new PCT-based instrument system.  ... ready for shipment by mid-October and that additional ... a rate of about one per week thereafter.  ...
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners ... Future to Benefit the Radiation Oncology Institute (ROI), hosted ... at Golden Gate Park in San Francisco.  ... Moore , CEO of Radiation Business Solutions, "but ... have raised over $70,000 for the ROI this year. ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3
... CHADDS FORD, Pa., Oct. 22 Endo Pharmaceuticals (Nasdaq: ... and Company 21st Annual Healthcare Conference on Tuesday, November 2, 2010, ... Endo, will review the company,s products and development programs. ... from Endo,s website at www.endo.com under the investors section. ...
... Pharmaxis (ASX: PXS) today announced significant results of pooled ... III trials of Bronchitol (inhaled mannitol) in people with ... presented for the first time at the North American ... addition, more results from the second trial (CF302) have ...
Cached Medicine Technology:Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 2Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 3Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 4Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 5
(Date:9/21/2014)... AstraZeneca’s Pulmicort is an ICS ... is used prophylactically for the maintenance treatment of ... budesonide, is an anti-inflammatory corticosteroid with a high ... includes the Pulmicort Flexhaler (budesonide) for adults and ... Pulmicort Respules for children between one and eight ...
(Date:9/21/2014)... than a quarter of house fires are started by ... ways. The first type of dryer fire occurs when the ... dryer fire occurs when lint builds up in the dryer vent ... malfunctioning electrical systems so if it doesn’t appear to be working ... some ways that you can prevent dryer fires. , Clean the ...
(Date:9/21/2014)... Burnaby Physiotherapists at Absolute PhysioCare & Sports ... to help them with preventative care. This is part ... will help clients understand their problem in a better ... in the healing process. With higher knowledge of their ... to facilitate the therapy that is initiated by the ...
(Date:9/21/2014)... New York (PRWEB) September 21, 2014 ... of their Risk Management Portal designed for Diocesan ... with the intent to support effective risk management ... scheduled to go live coinciding with Waldorf’s exhibition ... 21-24, 2014. , These applications were developed in ...
(Date:9/21/2014)... 2014 The asthma market saw ... it has become saturated with relatively efficacious standard ... (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and ... generic competition. However, the launch of seven novel ... therapies delivered by the next-generation inhalers will strongly ...
Breaking Medicine News(10 mins):Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Restoration Local Offers Tips to Avoid Dryer Fires 2Health News:Restoration Local Offers Tips to Avoid Dryer Fires 3Health News:Burnaby Physiotherapists Now Provide Educational Information for Preventative Care 2Health News:Waldorf Risk Solutions Releases New Risk Management Portal 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4
... 7-9 in Las Vegas , ... Denver -- As part of its ... Water Works Association (AWWA), the authoritative resource on safe water, today ... , Oct. 7-9, 2009, in Las Vegas., , , , ,Debuted last ...
... comes as use of stimulant for enhanced mental function is ... -- A drug used to treat narcolepsy is increasingly being ... evidence that it also harbors the potential for abuse. , ... brain, the new study shows. , "This drug does seem ...
... Carestream Health, Inc. is a leading provider of dental and medical ... ... NY (PRWEB) March 17, 2009 -- Carestream Health, Inc., announced new ... (DR) imaging systems that provide direct digital capture of medical x-ray ...
... The Netherlands A number of updated guidelines will be ... of Urology (EAU) held in Stockholm, from 17 though 21 ... based on the extended text documents will also be available ... of clinical guidelines is one of the core activities of ...
... Ill., March 17 It happens in an instant, standing ... Vice President Joe Biden,s mother. For 92 year old ... guarding against taking a tumble is fast becoming a full ... now take added precautions to help prevent a fall and ...
... tobacco, and drug useOLYMPIA, Wash., March 17 A ... good choices about their health. Still, far too many ... behavior.The Healthy Youth Survey focuses on health risk behaviors. ... by more than 210,000 public school kids around the ...
Cached Medicine News:Health News:AWWA partners with WaterSmart Innovations conference 2Health News:Narcolepsy Drug Might Be Addictive 2Health News:Narcolepsy Drug Might Be Addictive 3Health News:Carestream Health Announces New Orders From from U.S. Healthcare Facilities For for Its Digital Radiography Solutions 2Health News:EAU launches new clinical guidelines for 2009 -- kidney cancer 2Health News:Safety Alert: From the American Academy of Orthopaedic Surgeons 2Health News:New Survey Results Give a Window Into Teen Behavior and Risks 2Health News:New Survey Results Give a Window Into Teen Behavior and Risks 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: